NCT06765265 Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
| NCT ID | NCT06765265 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | King Edward Medical University |
| Condition | Acute Coronary Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 152 participants |
| Start Date | 2025-01-05 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 152 participants in total. It began in 2025-01-05 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months
Eligibility Criteria
Inclusion Criteria: Acute Coronary Syndrome 25 OH-Vitamin D levels between 30-70ng/ml Exclusion Criteria: Hypercalcemia hypocalcemia pregnancy lactation hypersensitivity to statins hypothyroidism Deranged LFTs \& RFTs Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)
Contact & Investigator
Uzma Malik
STUDY CHAIR
King Edward Medical University
Frequently Asked Questions
Who can join the NCT06765265 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Acute Coronary Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06765265 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06765265 currently recruiting?
Yes, NCT06765265 is actively recruiting participants. Contact the research team at ahshah12@hotmail.com for enrollment information.
Where is the NCT06765265 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT06765265 clinical trial?
NCT06765265 is sponsored by King Edward Medical University. The principal investigator is Uzma Malik at King Edward Medical University. The trial plans to enroll 152 participants.